Welcome!

News Feed Item

Trimel Provides Corporate Update and First Quarter 2014 Financial Results

TORONTO, ONTARIO -- (Marketwired) -- 05/08/14 -- Trimel Pharmaceuticals Corporation (TSX: TRL) today provided an overview of its corporate accomplishments and reported financial results for the three month period ended March 31, 2014.

2014 Corporate Developments

As previously communicated, the Food and Drug Administration's ("FDA") review of CompleoTRT™ is progressing and is in its final stages. Barring any unforeseen circumstances, the Company expects to obtain a final decision regarding marketing approval in late May 2014.

With respect to the ongoing Phase II clinical trial for Tefina™, a product being developed for the treatment of Female Orgasmic Disorder, the last patient enrolled in the study has now completed the applicable treatment protocol. Full database lock is scheduled to occur on May 9, 2014. The Company anticipates receiving top-line results from the study by the end of May 2014.

During the 2014 first quarter, the Company successfully raised net proceeds of CAD $10.5 million (US$9.5 million) from a private placement which closed on February 21, 2014. In connection with the private placement, the Company issued 14,829,676 common shares at a price of CAD$0.711 per share.

Shareholder Meeting and Earnings Call

Shareholders are advised that an annual general and special meeting of shareholders will occur on June 12, 2014 at 11:00 a.m. (Toronto time) at The Toronto Region Board of Trade, First Canadian Place, 77 Adelaide Street West, Toronto, Ontario. Shareholders of record as of May 6, 2014 shall be entitled to vote on all matters at the meeting, and a detailed management information circular and voting materials will be mailed to shareholders shortly. If shareholders have not received their materials by June 1, 2014, they are encouraged to follow up directly with their brokers at such time.

Additionally, shareholders are reminded of the conference call to discuss the Company's first quarter results to be held on May 9, 2014 at 8:30 a.m. (Toronto time). To access the call live, please dial 416-340-2216 or 1-866-223-7781. Listeners are encouraged to dial in 10 minutes before the call begins to avoid delays. A replay of the conference call will be available until 7:00 p.m. (Toronto time) on Friday, May 16, 2014 by dialing 905-694-9451 or 1-800-408-3053, using access code: 6382379#.

Financial Results for the Three Months Ended March 31, 2014

For the three month period ended March 31, 2014, Trimel incurred Research and Development ("R&D") expenses of US$2.7 million, as compared to US$4.9 million for the comparable 2013 period. Higher R&D expenses for the 2013 first quarter reflected CompleoTRT™ expenses associated with the NDA submission in April 2013, a $2.0 million time-based milestone payment which became due on March 31, 2013, and development materials and mould prototypes for CompleoTRT™. First quarter 2014 R&D expenses were impacted by higher Tefina™ clinical trial costs as this study progressed to its completion in April 2014.

Trimel incurred General and Administrative expenses of US$1.3 million for the three month period ended March 31, 2014, as compared to US$3.4 million for the comparable 2013 period. The decrease in spending was primarily attributable to lower legal fees related to arbitration, corporate and intellectual property matters. The arbitration matters were settled pursuant to a December 21, 2013 agreement.

For the three month period ended March 31, 2014, the Company incurred a net loss of US$0.02 per share, as compared to a net loss of US$0.09 per share for the comparable 2013 period.

At March 31, 2014, the Company had total assets of US$27.2 million, as compared to US$28.1 million at December 31, 2013 and total liabilities of US$8.4 million at March 31, 2014, as compared to US$14.6 million at December 31, 2013. The US$6.2 million decrease in total liabilities was primarily impacted by a US$4.25 million milestone obligation paid to M&P Patent AG, payments related to the Company's debt facility and payments related to the purchase of CompleoTRT™ inventory.

The Company had a net cash outflow of US$0.6 million for the three months ended March 31, 2014. After adjusting this net cash outflow for the US$9.5 million private placement and the US$4.25 million milestone payment to M&P Patent AG which was accrued at the end of fiscal 2013 and paid on January 2, 2014, the Company's burn rate during the 2014 first quarter was approximately US$5.85 million, or an average of US$1.95 million per month. The Company believes it has sufficient resources to fund its ongoing activities through 2014, depending on the timing of further clinical activities and barring unforeseen events.

The information set out above is in summary form. Readers are encouraged to review the Company's annual information form, financial statements (and accompanying notes), together with management's discussion and analysis available on SEDAR at www.sedar.com and on the Company's website at www.trimelpharmaceuticals.com.

About Trimel

Trimel is a specialty pharmaceutical company developing medications for male hypogonadism, female sexual dysfunction and various respiratory disorders. An NDA for CompleoTRT™, a product utilizing Trimel's licensed bioadhesive intranasal gel technology, has been accepted for review by the FDA for regulatory approval in the United States. For more information, please visit www.trimelpharmaceuticals.com.

Notice regarding forward-looking statements:

Information in this press release that is not current or historical factual information may constitute forward looking information within the meaning of securities laws. Implicit in this information are assumptions regarding our future operational results. These assumptions, although considered reasonable by the company at the time of preparation, may prove to be incorrect. Readers are cautioned that actual performance of the company is subject to a number of risks and uncertainties, including that CompleoTRT™ may not be approved by the FDA or that any approval may be delayed, and could differ materially from what is currently expected as set out above. For more exhaustive information on these risks and uncertainties you should refer to our annual information form dated March 5, 2014 which is available at www.sedar.com. Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time, whether as a result of new information, future events or otherwise, except as required by applicable securities law.



                     TRIMEL PHARMACEUTICALS CORPORATION
       CONDENSED INTERIM CONSOLIDATED STATEMENT OF FINANCIAL POSITION
                            AS AT MARCH 31, 2014
                                 UNAUDITED
                        (expressed in U.S. Dollars)

                                   ASSETS
                                                  March 31,    December 31,
                                                       2014            2013
                                            --------------------------------

CURRENT
  Cash                                         $ 17,507,518    $ 18,111,145
  Restricted cash                                    22,614          23,505
  Inventory                                       2,179,094       1,913,772
  Prepaids and other assets                       1,716,208       1,582,924
                                            --------------------------------
                                                 21,425,434      21,631,346

NON-CURRENT ASSETS
  Property and equipment, net                     2,582,675       3,273,196
  Intangible assets                               3,142,850       3,216,800
                                            --------------------------------
TOTAL ASSETS                                   $ 27,150,959    $ 28,121,342
                                            --------------------------------


                                LIABILITIES

CURRENT
  Accounts payable and accrued liabilities      $ 4,438,903     $ 9,864,079
  Current portion of long-term debt, net of
   issuance costs                                 2,846,946       2,834,639
                                            --------------------------------
                                                  7,285,849      12,698,718

LONG-TERM
  Long-term debt, net of issuance costs           1,092,120       1,827,082
  Derivative financial instrument                    41,676          20,977
                                            --------------------------------
TOTAL LIABILITIES                               $ 8,419,645    $ 14,546,777
                                            --------------------------------


                            SHAREHOLDERS' EQUITY

Share capital                                   129,211,443     119,741,040
Warrants                                          1,039,705       1,039,705
Contributed surplus                               8,058,386       7,987,237
Accumulated other comprehensive income
 (loss)                                          (3,445,938)     (1,639,862)
Deficit                                        (116,132,282)   (113,553,555)
                                            --------------------------------
TOTAL SHAREHOLDERS' EQUITY                       18,731,314      13,574,565
                                            --------------------------------
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY     $ 27,150,959    $ 28,121,342
                                            --------------------------------

                     TRIMEL PHARMACEUTICALS CORPORATION
  CONDENSED INTERIM CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS
             FOR THE THREE MONTHS ENDED MARCH 31, 2014 AND 2013
                                 UNAUDITED
                        (expressed in U.S. Dollars)

                                                        2014           2013
                                              ------------------------------
EXPENSES
  Research and development                       $ 2,709,961    $ 4,874,417
  General and administrative                       1,275,065      3,402,311
                                              ------------------------------
  Total operating expenses                         3,985,026      8,276,728
                                              ------------------------------

FINANCE COSTS, NET
  Interest on long-term debt and other
   financing costs                                   176,712        288,655
  Interest income                                    (19,643)        (4,143)
  Foreign exchange (gain)/ loss                   (1,584,067)         3,370
  Change in fair value of derivative financial
   instrument                                         20,699       (135,967)
                                              ------------------------------
                                                  (1,406,299)       151,915
                                              ------------------------------
TOTAL EXPENSES                                     2,578,727      8,428,643
                                              ------------------------------
LOSS BEFORE INCOME TAXES                          (2,578,727)    (8,428,643)

INCOME TAXES                                               -              -
                                              ------------------------------
NET LOSS                                        $ (2,578,727)  $ (8,428,643)
                                              ------------------------------
                                              ------------------------------

OTHER COMPREHENSIVE LOSS, NET OF INCOME TAX
Items that may be reclassified subsequently to
 profit or loss:
  Foreign currency translation adjustment         (1,806,076)      (126,487)
                                              ------------------------------
TOTAL COMPREHENSIVE LOSS FOR THE PERIOD         $ (4,384,803)  $ (8,555,130)
                                              ------------------------------
                                              ------------------------------
Basic and diluted weighted average shares
 outstanding                                     154,722,955     90,796,762

Basic and diluted net loss per common share          $ (0.02)       $ (0.09)

                     TRIMEL PHARMACEUTICALS CORPORATION
 CONDENSED INTERIM CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY
                                 (DEFICIENCY)
             FOR THE THREE MONTHS ENDED MARCH 31, 2014 AND 2013
                                  UNAUDITED
                         (expressed in U.S. Dollars)

                                                                 Contributed
                               Share capital        Warrants         surplus
                            ------------------------------------------------

Balance, January 1, 2013        $ 78,214,661     $ 3,452,607     $ 4,318,927

Net loss for the period                    -               -               -

Cumulative translation
 adjustment                                -               -               -

----------------------------------------------------------------------------

Total comprehensive loss for
 the period                                -               -               -

Share based compensation                   -               -         477,545
----------------------------------------------------------------------------
Balance as at March 31, 2013    $ 78,214,661     $ 3,452,607     $ 4,796,472
----------------------------------------------------------------------------
----------------------------------------------------------------------------

Balance, January 1, 2014       $ 119,741,040     $ 1,039,705     $ 7,987,237

Net loss for the period                    -               -               -

Cumulative translation
 adjustment                                -               -               -

----------------------------------------------------------------------------

Total comprehensive loss for
 the period                                -               -               -

Common shares, net of share
 issuance costs                    9,470,403               -               -

Share based compensation                   -               -          71,149
----------------------------------------------------------------------------
Balance as at March 31, 2014   $ 129,211,443     $ 1,039,705     $ 8,058,386
----------------------------------------------------------------------------


                     TRIMEL PHARMACEUTICALS CORPORATION
CONDENSED INTERIM CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY
                                (DEFICIENCY)
             FOR THE THREE MONTHS ENDED MARCH 31, 2014 AND 2013
                                 UNAUDITED
                        (expressed in U.S. Dollars)

                                Accumulated
                                      other
                              comprehensive
                                     income
                                     (loss)         Deficit           Total
                            ------------------------------------------------

Balance, January 1, 2013          $ 362,920   $ (81,598,627)    $ 4,750,488

Net loss for the period                   -      (8,428,643)     (8,428,643)

Cumulative translation
 adjustment                        (126,487)              -        (126,487)

----------------------------------------------------------------------------

Total comprehensive loss for
 the period                        (126,487)     (8,428,643)     (8,555,130)

Share based compensation                  -               -         477,545
----------------------------------------------------------------------------
Balance as at March 31, 2013      $ 236,433   $ (90,027,270)   $ (3,327,097)
----------------------------------------------------------------------------
----------------------------------------------------------------------------

Balance, January 1, 2014       $ (1,639,862) $ (113,553,555)   $ 13,574,565

Net loss for the period                   -      (2,578,727)     (2,578,727)

Cumulative translation
 adjustment                      (1,806,076)              -      (1,806,076)

----------------------------------------------------------------------------

Total comprehensive loss for
 the period                      (1,806,076)     (2,578,727)     (4,384,803)

Common shares, net of share
 issuance costs                           -               -       9,470,403

Share based compensation                  -               -          71,149
----------------------------------------------------------------------------
Balance as at March 31, 2014   $ (3,445,938) $ (116,132,282)   $ 18,731,314
----------------------------------------------------------------------------

                     TRIMEL PHARMACEUTICALS CORPORATION
           CONDENSED INTERIM CONSOLIDATED STATEMENT OF CASH FLOWS
             FOR THE THREE MONTHS ENDED MARCH 31, 2014 AND 2013
                                 UNAUDITED
                        (expressed in U.S. Dollars)

                                                        2014           2013
                                              ------------------------------

CASH FLOWS FROM OPERATING ACTIVITIES
----------------------------------------------
  Net loss for the period                       $ (2,578,727)  $ (8,428,643)
  Items not requiring an outlay of cash:
    Adjustment for foreign exchange
     (gain)/loss                                  (1,250,269)        63,742
    Amortization of intangible assets                 73,950         73,950
    Depreciation of property and equipment           635,799        170,414
    Interest on long-term debt and other
     financing costs                                 176,712        288,655
    Change in fair value of derivative
     financial instrument                             20,699       (135,967)
    Share based compensation                          71,149        477,545
  Net changes in non-cash working capital
   items related to operating activities:
    Inventory                                       (265,322)             -
    Prepaids and other assets                       (137,696)      (158,947)
    Accounts payable and accrued liabilities      (5,404,597)     3,561,219
  Provisions                                               -         (7,784)
                                              ------------------------------
                                                  (8,658,302)    (4,095,816)
                                              ------------------------------

CASH FLOWS FROM FINANCING ACTIVITIES
----------------------------------------------
  Proceeds from issuance of common shares, net
   of financing costs                              9,470,403              -
  Financing costs, long-term debt                    (35,757)             -
  Payment of long-term debt obligations             (750,000)      (500,000)
  Payment of capital lease obligations                     -       (103,705)
  Interest paid                                      (78,836)      (130,311)
                                              ------------------------------
                                                   8,605,810       (734,016)
                                              ------------------------------

CASH FLOWS FROM INVESTING ACTIVITIES
----------------------------------------------
  Acquisition of property and equipment              (27,103)       (34,796)
  Proceeds from sale of property and equipment             -          1,015
                                              ------------------------------
                                                     (27,103)       (33,781)
                                              ------------------------------


NET DECREASE IN CASH FOR THE PERIOD                  (79,595)    (4,863,613)

Exchange (loss) on cash                             (524,032)      (144,542)

CASH BEGINNING OF PERIOD                          18,111,145      9,216,999
                                              ------------------------------

CASH END OF PERIOD                              $ 17,507,518    $ 4,208,844
                                              ------------------------------

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
Tintri VM-aware storage is the simplest for virtualized applications and cloud. Organizations including GE, Toyota, United Healthcare, NASA and 6 of the Fortune 15 have said "No to LUNs." With Tintri they manage only virtual machines, in a fraction of the footprint and at far lower cost than conventional storage. Tintri offers the choice of all-flash or hybrid-flash platform, converged or stand-alone structure and any hypervisor. Rather than obsess with storage, leaders focus on the business app...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
Big Data, cloud, analytics, contextual information, wearable tech, sensors, mobility, and WebRTC: together, these advances have created a perfect storm of technologies that are disrupting and transforming classic communications models and ecosystems. In his session at @ThingsExpo, Erik Perotti, Senior Manager of New Ventures on Plantronics’ Innovation team, provided an overview of this technological shift, including associated business and consumer communications impacts, and opportunities it m...
WebRTC is about the data channel as much as about video and audio conferencing. However, basically all commercial WebRTC applications have been built with a focus on audio and video. The handling of “data” has been limited to text chat and file download – all other data sharing seems to end with screensharing. What is holding back a more intensive use of peer-to-peer data? In her session at @ThingsExpo, Dr Silvia Pfeiffer, WebRTC Applications Team Lead at National ICT Australia, looked at differ...
For organizations that have amassed large sums of software complexity, taking a microservices approach is the first step toward DevOps and continuous improvement / development. Integrating system-level analysis with microservices makes it easier to change and add functionality to applications at any time without the increase of risk. Before you start big transformation projects or a cloud migration, make sure these changes won’t take down your entire organization.
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo 2016 in New York. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place June 6-8, 2017, at the Javits Center in New York City, New York, is co-located with 20th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry p...
SYS-CON Events announced today that IoT Now has been named “Media Sponsor” of SYS-CON's 20th International Cloud Expo, which will take place on June 6–8, 2017, at the Javits Center in New York City, NY. IoT Now explores the evolving opportunities and challenges facing CSPs, and it passes on some lessons learned from those who have taken the first steps in next-gen IoT services.
The Internet of Things can drive efficiency for airlines and airports. In their session at @ThingsExpo, Shyam Varan Nath, Principal Architect with GE, and Sudip Majumder, senior director of development at Oracle, discussed the technical details of the connected airline baggage and related social media solutions. These IoT applications will enhance travelers' journey experience and drive efficiency for the airlines and the airports.
SYS-CON Events announced today that WineSOFT will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Based in Seoul and Irvine, WineSOFT is an innovative software house focusing on internet infrastructure solutions. The venture started as a bootstrap start-up in 2010 by focusing on making the internet faster and more powerful. WineSOFT’s knowledge is based on the expertise of TCP/IP, VPN, SSL, peer-to-peer, mob...
DevOps is being widely accepted (if not fully adopted) as essential in enterprise IT. But as Enterprise DevOps gains maturity, expands scope, and increases velocity, the need for data-driven decisions across teams becomes more acute. DevOps teams in any modern business must wrangle the ‘digital exhaust’ from the delivery toolchain, "pervasive" and "cognitive" computing, APIs and services, mobile devices and applications, the Internet of Things, and now even blockchain.
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, whic...
Have you ever noticed how some IT people seem to lead successful, rewarding, and satisfying lives and careers, while others struggle? IT author and speaker Don Crawley uncovered the five principles that successful IT people use to build satisfying lives and careers and he shares them in this fast-paced, thought-provoking webinar. You'll learn the importance of striking a balance with technical skills and people skills, challenge your pre-existing ideas about IT customer service, and gain new in...
WebRTC sits at the intersection between VoIP and the Web. As such, it poses some interesting challenges for those developing services on top of it, but also for those who need to test and monitor these services. In his session at WebRTC Summit, Tsahi Levent-Levi, co-founder of testRTC, reviewed the various challenges posed by WebRTC when it comes to testing and monitoring and on ways to overcome them.
SYS-CON Events announced today that Catchpoint Systems, Inc., a provider of innovative web and infrastructure monitoring solutions, has been named “Silver Sponsor” of SYS-CON's DevOps Summit at 18th Cloud Expo New York, which will take place June 7-9, 2016, at the Javits Center in New York City, NY. Catchpoint is a leading Digital Performance Analytics company that provides unparalleled insight into customer-critical services to help consistently deliver an amazing customer experience. Designed ...
SYS-CON Events announced today that CA Technologies has been named “Platinum Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY, and the 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. CA Technologies helps customers succeed in a future where every business – from apparel to energy – is being rewritten by software. From ...